We thus performed a therapeutic experiment comparing romidepsin (approved use in relapsed/refractory PTCLs), rituximab, elotuzumab (anti‐SLAMF7 antibody approved for use in multiple myeloma), and combinations of these agents. Here, SLAMF7 is linked to AL amyloidosis.